Argentine drugmaker Biosidus has opened the door to new shareholders: the investment funds Acon Investments and Humus Capital Partners, which will now control the company.
Pharmabiz has learned that Biosidus, which had been owned by the García Belmonte family since the divisino of Grupo Sidus in 2010 is being reshaped through the arrival of new shareholders.
According to an official release from the company, two investment funds will take control of the biosimilars business. One of them is Washington and Los Angeles-based Acon Investments, which has a presence in Mexico, Brazil and Colombia and has a foot in the healthcare sector through companies such as BioMatrix and Refac Optical. Visit site.
Santiago García Belmonte will continue as CEO and will remain a shareholder of the firm, Pharmabiz has learned. The company says it will continue its international expansion while maintaining its plants in Bernal and Almagro.
The other investor is Argentine Humus Capital Partners, founded in 2010 by ex-McKinsey employee Ramiro Lauzan to find opportunities in Argentina. Visit site.
Biosidus was reticent about the value of the transaction and the exact percentage that the two funds will own. It is understood that the company had been seeking new partners for some time in order to raise capital.
Biosidus has two plants located in Bernal, in Buenos Aires Province, and Almagro, in the Buenos Aires City. Its star products include the bosimilars Osteofortil; Escleroferon; Blastoferon; Neutromax; and Hemax.
